Ocugen Prepares for Pivotal Conference Season with Promising Retinal Gene Therapy Data

A string of positive clinical readouts has given Ocugen a clear narrative to bring to ophthalmology’s biggest gatherings this month. The company’s three-pronged gene therapy pipeline, built on a “gen-agnostic” platform that targets modifier genes rather than individual mutations, will be on full display at the American Society of Retina Specialists meeting starting July 17. Earlier in the week, CEO Shankar Musunuri also presented at the Piper Sandler Virtual Ophthalmology Day and the OIS Retina Innovation Summit.

The data underpinning those presentations are concrete. In the Phase 2 ArMaDa study for geographic atrophy, a Disease-modifying therapy designated OCU410 showed a 31 percent reduction in lesion growth at 12 months in the optimal mid-dose group — hitting the primary endpoint. Selected patient subgroups saw an even stronger 33 percent slowdown. No drug-related serious adverse events have been reported across any of the three programs.

Even more striking are the Phase 1 results for OCU410ST, targeting Stargardt disease. Treated eyes exhibited 54 percent less growth of atrophic lesions compared with the untreated fellow eyes in the same patients. The company’s third asset, OCU400 for retinitis pigmentosa, rounds out a pipeline that Ocugen believes can address broad patient populations with a single injection.

The regulatory timeline is now taking shape. For OCU400, a rolling Biologics License Application is slated to begin in the third quarter of 2026, with potential full approval following in 2027. The Phase 3 study for that candidate has already completed enrollment at 140 patients — the company says it is the largest gene therapy trial of its kind. OCU410ST pivotal data are expected in the second quarter of 2027, with a BLA submission targeted for mid-2027. For geographic atrophy, the Phase 3 trial — designed with fewer than 300 patients in an adaptive protocol under review with regulators in the US and Europe — is scheduled to kick off in the third quarter of 2026, and Ocugen aims to file for approval in 2028.

Should investors sell immediately? Or is it worth buying Ocugen?

The stock has reflected the pipeline’s momentum, albeit with considerable volatility. Ocugen shares closed at €1.29 on Friday, up 0.94 percent on the day. Over the past 30 days the stock has gained nearly 25 percent, and on a year-to-date basis it has climbed more than 32 percent. Yet the weekly picture tells a different story — a 3.58 percent decline, and the stock still trades roughly 45 percent below its 52-week high of €2.35 reached in March. The distance from the August 2025 low of €0.82 is about 57 percent. The company’s market capitalization stands at around €436 million, and annualized 30-day volatility exceeds 67 percent.

Ocugen’s finances look secure enough to carry it through those milestones. A convertible note issued in May provides funding into 2028, and a licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea offers an additional revenue stream. Technical indicators are neutral for now — the relative strength index sits at 54.5, neither overbought nor oversold.

Analyst expectations, however, remain far more bullish than the current price suggests. The average price target implies an upside of more than 670 percent from today’s levels — a gap that underscores how cautious the market remains despite the clinical progress. Whether the data presentations at ASRS and other conference stops this week can start closing that divide will be the next test for the stock.